Ewing Sarcoma

NCI Definition: A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms. [1]

Clinical Trials

View Clinical Trials for Ewing Sarcoma

There are 37 clinical trials for Ewing sarcoma, of which 27 are open and 10 are completed or closed. Of the trials that contain Ewing sarcoma as an inclusion criterion, 1 is early phase 1 (1 open), 17 are phase 1 (9 open), 6 are phase 1/phase 2 (6 open), 12 are phase 2 (10 open), and 1 is no phase specified (1 open).

EWSR1, EWSR1-FLI1, and ATM are the most frequent gene inclusion criteria for Ewing sarcoma clinical trials [3].

Trials Investigating Ewing Sarcoma by Gene and Recruiting Status

Cyclophosphamide, temozolomide, and gemcitabine are the most common interventions in Ewing sarcoma clinical trials.

Drugs Being Investigated in Ewing Sarcoma Trials by Recruiting Status

Significant Genes in Ewing Sarcoma

ABL1 +

ABL1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains AFF1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AKT1 +

AKT1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT2 +

AKT2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 +

AKT3 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATM +

ATM is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATR +

ATR is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

AXL +

AXL is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 +

BARD1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRCA1 +

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRCA2 +

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRIP1 +

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 +

CDK12 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 +

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 +

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CRKL +

CRKL is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

DEK +

DEK is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains DEK status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

EWSR1 +

EWSR1 is an inclusion eligibility criterion in 8 clinical trials for Ewing sarcoma, of which 7 are open and 1 is closed. Of the trials that contain EWSR1 status and Ewing sarcoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCA +

FANCA is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB +

FANCB is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC +

FANCC is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 +

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE +

FANCE is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF +

FANCF is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG +

FANCG is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI +

FANCI is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL +

FANCL is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM +

FANCM is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FLI1 +

FLI1 is an inclusion eligibility criterion in 3 clinical trials for Ewing sarcoma, of which 3 are open and 0 are closed. Of the trials that contain FLI1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FUS +

FUS is an inclusion eligibility criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain FUS status and Ewing sarcoma as inclusion criteria, 2 are phase 1 (2 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MCPH1 +

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM +

MECOM is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MET +

MET is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MRE11A +

MRE11A is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MTOR +

MTOR is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYCN +

MYCN is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and Ewing sarcoma as inclusion criteria, 1 is no phase specified (1 open) [3].

NBN +

NBN is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PALB2 +

PALB2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA +

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CG +

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 +

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 +

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN +

PTEN is an inclusion eligibility criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

RAD50 +

RAD50 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 +

RAD51 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B +

RAD51B is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C +

RAD51C is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51D +

RAD51D is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD54L +

RAD54L is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RET +

RET is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR +

RICTOR is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains RPN1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RPTOR +

RPTOR is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SLX4 +

SLX4 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TAF15 +

TAF15 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TAF15 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 +

TP53 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TSC1 +

TSC1 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 +

TSC2 is an inclusion eligibility criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

Disease Details

Synonyms

ES, Ewing sarcoma, Ewing's Tumor, Ewing's Sarcoma

Parent(s)

Sarcoma

Children

Ewing Sarcoma of Bone, Extraskeletal Ewing Sarcoma, and Localized Ewing Sarcoma

OncoTree Name

Ewing Sarcoma

OncoTree Code

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Ewing Sarcoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Ewing Sarcoma

Disease Details

References

About

Molecular Medicine

Content Types